我们旨在鉴定潜在与银屑病关节炎(PsA)患者治疗反应相关的lncRNAs的表达谱,用作预测药物治疗有效性的潜在基因组生物标志物。此外,我们使用疾病活动指数的临床参数评估了lncRNAs遗传变异与治疗应答之间可能的关联.对于表达研究,我们收集了48名接受治疗的PsA患者,监测12个月的治疗反应。我们最初使用PCR阵列,然后,我们用qRT-PCR对结果进行了验证。我们还对163例接受治疗的PsA患者进行了回顾性基因分型。首先,我们观察到响应者和非响应者患者之间的表达水平存在显着差异,用TNFi治疗的PsA患者组中的4个lncRNA和用IL17i治疗的患者组中的3个lncRNA。然后,我们证实,与反应者相比,无反应者患者的MEG3表达显着降低,还分别考虑接受TNFi和IL17i治疗的单组患者。此外,我们的结果似乎突出了rs941576(MEG3)变异等位基因对疾病活动指数的潜在剂量依赖性效应.我们的研究表明lncRNAMEG3在对生物药物的治疗反应中的可能作用。
We aimed to identify an expression profile of lncRNAs potentially related to treatment response in Psoriatic arthritis (PsA) patients, to be used as potential genomic biomarkers predictors of drug treatment effectiveness. In addition, we evaluated a possible association between lncRNAs genetic variants and the response to therapy using the clinical parameter of Disease Activity Index. For the expression
study, we collected 48 treated PsA patients, monitoring the treatment response for 12 months. We initially used PCR Array and, then, we validated the results with qRT-PCR. We also retrospectively genotyped 163 treated PsA patients. Firstly, we observed a significant difference in the expression level between Responder and non-Responder patients, of 4 lncRNAs in the group of PsA patients treated with TNFi and of 3 lncRNAs in the group of patients treated with IL17i. Then, we confirmed a significant decrease of
MEG3 expression in non-Responder patients compared to Responders, also considering separately the single groups of patients treated with TNFi and IL17i. In addition, our results seem to highlight a potential dose-dependent effect of rs941576 (
MEG3) variant allele on Disease Activity Index. Our
study suggests a possible role of the lncRNA
MEG3 in the treatment response to biological drugs.